Jul. 23, 2026
SEONGNAM, SOUTH KOREA — South Korean biotechnology company Rznomics has received an additional research payment from Eli Lilly and Company under the companies’ ongoing collaboration to develop RNA-editing therapies for hereditary hearing loss, according to multiple Korean media reports citing the company. The development was first reported by Seoul Economic Daily, one of South Korea’s leading business publications, which reported that Rznomics
















